Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Porcine insulin may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for The name of your medicine is Hypurin Porcine Insulin. Hypurin Porcine is the brand name for a range of highly purified porcine (pig) insulin injections. Hypurin Porcine Neutral is a sterile, clear solution of porcine insulin (100 international units/ml). It is short acting. Hypurin Porcine Isophane is a sterile, white suspension of porcine insulin (100 international units/ml) with protamine sulfate and zinc chloride in water. It is longer acting than Hypurin Porcine Neutral. Hypurin Porcine 30/70 Mix is a sterile, white suspension of porcine neutral and isophane insulins (100 international units/ml). It is intermediate acting. What Hypurin is used for Hypurin contains insulin which is a natural hormone, made by a gland called the pancreas. Insulin plays a key role in the way the body uses carbohydrate, fat and protein. Hypurin Porcine is used for the treatment of insulindependent diabetes mellitus. In this type of diabetes, your pancreas does not make enough insulin to control the level of sugar in your blood. It can be treated by controlling your diet and taking insulin. Hypurin Porcine has been prescribed for you as a substitute for your own insulin.
e Hypurin Do not use Hypurin
Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.
Hypurin Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. What dose is needed? There is no 'standard' dose of insulin. Each person with diabetes has their own dose calculated according to their needs. Your doctor will decide which dose is best for you and which insulin to use. Always follow your doctor's instructions exactly and also follow any special instructions or warnings that appear on the label that the pharmacist has put on the package. Dosage adjustments Patients with disease of the liver, kidneys, adrenal, pituitary or thyroid glands, or coeliac disease (symptoms may include severe diarrhoea and unintentional weight loss) may need lower doses. This dose may alter during illness (including infection and surgery), injury, emotional stress, during puberty, around the time of a menstrual period, and during pregnancy and after delivery. Lactating women may also require dosage adjustments. It may also change with your diet and lifestyle, particularly if you are exercising more. Patients transferred to Hypurin Porcine Insulins from other types of insulin may require dosage adjustments. Newly diagnosed diabetic patients may require dosage adjustments during the first weeks, months or years of treatment. If you do not understand or are in any doubt ask your doctor, pharmacist or diabetes nurse. Advice and checks to be made when using Hypurin Porcine Insulin
Customer
Wockhardt UK Limited
Colours Used
Description
HYPUR P 100U/ML 3ML CARTRIDGE COMMON LEAFLET
Black
Item Code
101972/8
Keyline (Non-Printing)
Profile
See uploaded annotated pdf
Cirrus_Info_Box
Size
148 x 350mm
Min.Point Size
Other
Market
UK
Language
English
Standard 296
Barcode Proof By
RPA
Proof No.
1
Date
02/07/2020
Body Text Fonts:
Pragmatica Cond.
Body Text Ctd.
–
Actual Min Point Size
8 pt
Injecting Hypurin Your doctor or diabetes nurse will advise you on how to inject your insulin.
Like all medicines, this medicine can cause side effects, although not everybody gets them. These include:
Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.
Hypurin Keep all cartridges, needles and pens out of the sight and reach of children.
What Hypurin Porcine Contains Hypurin Porcine Neutral is a sterile, clear solution of porcine insulin (100 international units/ml). It also contains m-cresol, phenol, glycerol and sodium phosphate. Hypurin Porcine Isophane is a sterile, white suspension of porcine insulin (100 international units/ml) with protamine sulfate and zinc chloride in water. It also contains m-cresol, phenol, glycerol and sodium phosphate. Hypurin Porcine 30/70 Mix is a sterile, white suspension of porcine neutral and isophane insulins (100 international units/ml). It also contains m-cresol, phenol, glycerol and sodium phosphate. What Hypurin Porcine looks like and contents of the pack Hypurin Porcine is available in packs of five glass cartridges, which contain 3ml of solution or suspension for use in pen injectors and glass vials, which contain 10ml of solution or suspension. Other formats: To listen to or request a copy of this information in Braille, large print or audio please call, free of charge: 0800 198 5000 (UK only) Please be ready to give the following information: Product name Reference number Hypurin® Porcine Neutral 29831/0124 100 IU/ml Insulin Injection Hypurin® Porcine Isophane 29831/0122 100 IU/ml Insulin Injection Hypurin® Porcine 30/70 Mix 29831/0119 100 IU/ml Insulin Injection Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF, UK. Manufacturer CP Pharmaceuticals Ltd, Ash Road North, Wrexham, LL13 9UF, UK. This leaflet was last revised in 06/2020
101972/8
Customer
Wockhardt UK Limited
Colours Used
Description
HYPUR P 100U/ML 3ML CARTRIDGE COMMON LEAFLET
Black
Item Code
101972/8
Keyline (Non-Printing)
Profile
See uploaded annotated pdf
Cirrus_Info_Box
Size
148 x 350mm
Min.Point Size
Other
Market
UK
Language
English
Standard 296
Barcode Proof By
RPA
Proof No.
1
Date
02/07/2020
Body Text Fonts:
Pragmatica Cond.
Body Text Ctd.
–
Actual Min Point Size
8 pt
The active substance in Hypurin Porcine Neutral Cartridges – PL 29831/0124 is porcine insulin.
Medicines with the same active substance, strength and form include: Hypurin Porcine 30/70 Mix Cartridges – PL 29831/0119, Hypurin Porcine 30/70 Mix Vials – PL 29831/0118, Hypurin Porcine Isophane Cartridges – PL 29831/0122. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Hypurin Porcine Neutral Cartridges – PL 29831/0124, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
The treatment of insulin dependent diabetes mellitus.
May be used for diabetics who require an insulin of prompt onset and short duration. It is a suitable preparation for admixture with longer acting insulins. It is particularly useful where intermittent, short term or emergency therapy is required, during initial stabilisation and in the treatment of labile diabetes.
Posology
To be determined by the physician according to the needs of the patient.
Method of administration
Usually administered subcutaneously but where necessary it may be given intramuscularly or intravenously. After subcutaneous injection onset of action occurs within 30-60 minutes with an overall duration of 6-8 hours. Maximum effect is exerted over the mid-range.
Hypurin® Porcine Neutral in cartridges is only suitable for subcutaneous injections from a reusable pen.
If administration by syringe, intravenous injection or infusion pump is necessary, a vial should be used.
Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).
Hypoglycaemia.
Hypersensitivity to insulin or to any of the excipients listed in section 6.1.
Hypoglycaemia: Susceptibility to hypoglycaemia may be increased by an inaccurate or excessive dosage of insulin, the omission of a meal by the patient or increased physical activity. Correct insulin administration and awareness of the symptoms of hypoglycaemia are essential to reduce the risk of hypoglycaemia (see section 4.9).
Blood or urinary glucose concentrations should be monitored and the urine tested for ketones by patients on insulin therapy.
Newly diagnosed diabetic patients may experience fluctuating insulin requirements during the first weeks, months or even years of treatment (the so-called 'honeymoon period').
Patients transferred to Hypurin® Porcine insulins from other commercially available preparations may require dosage adjustments.
The warning symptoms of hypoglycaemia may be changed, be less pronounced or absent in certain risk groups who should be advised accordingly. These include patients:
- in whom glycaemic control is greatly improved, e.g. by intensified insulin therapy
- with a long history of diabetes
- who are elderly
- receiving concomitant treatment with certain medicinal products e.g. beta blockers or clonidine
- who have experienced repeated episodes of hypoglycaemia.
Elderly diabetic patients are more susceptible to episodes of severe, rapid onset hypoglycaemia.
Combination of Hypurin® insulins with pioglitazone: Cases of cardiac failure have been reported when thiazolidinediones are used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and Hypurin® is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.
Insulin requirements may increase during illness (this includes infection and accidental and surgical trauma), puberty or emotional upset.
Insulin resistance is frequently associated with lipid disorders, hypertension and ischaemic heart disease. Patients with insulin resistance usually require more than 200 units of insulin daily. Insulin resistance of the type manifested by greatly increased insulin requirements may be due to factors including antibody formation although some diseases, such as infections, endocrine hyperfunctional states (e.g. acromegaly, Cushing's syndrome, thyrotoxicosis) or stress can contribute to insulin resistance.
Insulin requirements may decrease with liver disease, disease of the adrenal, pituitary or thyroid glands and coeliac disease. In patients with severe renal impairment, insulin requirements may fall and dosage reduction may be necessary. The compensatory response to hypoglycaemia may also be impaired.
Insulin requirements may be increased in the premenstrual period but may be reduced during or after a menstrual cycle.
Insulin requirements are usually reduced but occasionally increased during periods of increased activity.
Increase in subcutaneous blood flow, brought about by factors such as a hot bath, sunbathing/sunbed or sauna may increase the rate of absorption of insulin and increase the risk of hypoglycaemia occurring.
Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.
Drugs that may increase the requirement for insulin
Antipyschotics: chloropromazine
Corticosteroids
Diazoxide
Diuretics: thiazide diuretics or loop diuretics
Sympathomimetic agents
Thyroid hormone replacement therapy
Smoking may also antagonise the hypoglycaemic effect of insulin
Drugs that may decrease the requirement for insulin
ACE inhibitors
Alcohol: moderate or large amounts of alcohol (more than 2 units per day for women and more than 3 units per day for men) can decrease the requirements for insulin and may lead to hypoglycaemic attacks. Episodic heavy drinking ('binge' drinking) carries a particularly high risk of hypoglycaemic episodes.
Anabolic steroids
Analgesics: NSAIDS, or salicylates, particularly large doses of aspirin
Androgens: testosterone may enhance the hypoglycaemic effect of insulin
Anti-arrhythmics: disopyramide.
Concomitant use of insulin with quinidine may increase the risk of hypoglycaemia occurring.
Anti-depressants: monoamine oxidase inhibitors or fluoxetine.
Concomitant use of amitriptyline with insulin may lead to hypoglycaemia.
Antihypertensives: guanethidine
Antimalarials: concomitant use of insulin with antimalarials such as chloroquine or quinine may increase the risk of hypoglycaemia occurring.
Fenfluramine
Hormone antagonists: octreotide
Lipid-regulating drugs: fibrates
Mebendazole
Pentoxifylline: the hypoglycaemic activity of insulin may be potentiated by concomitant administration of high-dose pentoxifylline injection.
Tetracyclines: tetracyclines such as oxytetracycline
Drugs that may increase or decrease the requirements for insulin
Antihypertensives: clonidine. Signs and symptoms of hypoglycaemia may be masked by clonidine.
Beta blockers: beta blockers. Some of the warning signs of insulin-induced hypoglycaemia may be masked.
Calcium channel blockers: nifedipine may occasionally impair glucose tolerance.
Cyclophosphamide
Isoniazid
Lipid-regulating drugs: gemfibrozil
Oral contraceptives
Other interactions
Antidiabetics: Thiazolidinediones (pioglitazone) may induce oedema and/or heart failure with higher rates of heart failure when used concomitantly with insulin (see section 4.4).
Pregnancy
A decreased requirement for insulin may be observed in the early stages of pregnancy. However, in the second and third trimesters, insulin requirements may increase. Insulin requirements should therefore be assessed frequently by an experienced diabetic physician.
Maternal insulin requirements may decrease after delivery. As this decrease can be at an unpredictable rate, the maternal blood glucose should be closely monitored.
Congenital abnormality is more common in offspring of diabetic than non-diabetic women.
Lactation
Caution should be exercised when prescribing to lactating women. Lactating women may require adjustments in insulin dose and diet.
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).
Patients should be advised to take precautions to avoid hypoglycaemia whilst driving, this is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.
Immune system disorders:
Insulin hypersensitivity can occur with animal insulins, but appears less likely with purified insulins and there is minimal evidence that such effects occur with Hypurin insulins.
Neuropathic pain induced by rapid glycaemic control following insulin administration may occur.
Allergic reactions to phenol and m-cresol contained as preservative may occur.
• Local hypersensitivity: Local allergic reactions to insulin such as pruritus, erythema and oedema may occur at the injection site.
• Generalised hypersensitivity: Generalised hypersensitivity may produce urticaria, rash, nausea, dyspnoea or wheezing and, in rare cases, anaphylactic reactions. Severe, angioedema is a rare adverse effect of insulin treatment occurring most often at the initiation of therapy.
Metabolism and nutrition disorders:
• Hypoglycaemia is the most common adverse effect associated with insulin therapy. For symptoms of hypoglycaemia, refer to section 4.9, Overdosage.
• Hypokalaemia may occur with insulin therapy.
• Insulin therapy may lead to weight gain.
Skin and subcutaneous tissue disorders:
Lipodystrophy and cutaneous amyloidosis (frequency not known) may occur at the injections site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).
General disorders and administration site conditions:
Stinging or sensations of warmth or burning at the site of injection may also occur.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
a) Symptoms
Overdosage causes hypoglycaemia. Symptoms include yawning, hunger, pallor, restlessness, weakness, sweating, trembling, confusion, anxiety, nervousness, excitement, irritability, aggression, altered behaviour, deep respiration, cramps, headache, paraesthesia and/or numbness of the nose, mouth, fingers or toes, reduced consciousness, visual disturbance, including blurred vision and double vision, slurred speech, difficulty in finding words, difficulty in concentration, drowsiness, fatigue, convulsions, hemiplegia, paralysis, tachycardia and/or palpitations, myocardial ischaemia and cerebral oedema which, if untreated, will lead to collapse, coma and/or irreversible brain damage.
Hypokalaemia may also occur with insulin overdose.
b) Treatment
Mild hypoglycaemia will respond to oral administration of glucose or sugar and rest.
Moderately severe hypoglycaemia can be treated by intramuscular, intravenous or subcutaneous injection of glucagon followed by oral carbohydrate when the patient is sufficiently recovered.
For patients who are comatose or who have failed to respond to glucagon injection an intravenous injection of strong Dextrose Injection BP should be given.
Ask anything about Hypurin Porcine Neutral Cartridges – PL 29831/0124. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.